Is retatrutide available to the public?

Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or "off-label investigational" frameworks, but this carries significant legal and safety risk. Verify any provider's authorization carefully.

When might retatrutide receive FDA approval?

Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.

Home›Legal›Retatrutide in Pennsylvania

Educational — Not Legal AdviceUpdated May 10, 2026

Retatrutide in Pennsylvania: Legal Status & Provider Guide (2026)

Quick Answer

Retatrutide is a prescription substance in the United States. Retatrutide is an investigational triple-receptor agonist (GIP/GLP-1/glucagon) with no FDA approval. It cannot legally be compounded under federal law. Commercial availability outside of clinical trials is not authorized by the FDA. In Pennsylvania, compounding is governed by the Pennsylvania State Board of Pharmacy (PSBP). Pennsylvania certified registered nurse practitioners (CRNPs) may prescribe compounded medications including peptides within a collaborative agreement. Physician assistants also require supervision agreements. Pennsylvania has moderately permissive telehealth rules, allowing prescribing after an appropriate telehealth evaluation. Pennsylvania prescribers must hold an active Pennsylvania license to prescribe to Pennsylvania residents.

Federal Legal Status

FDA Approval Status

Not FDA-approved. Retatrutide is in Phase III clinical trials as of 2026. No NDA filed.

Compounding Pharmacy Rules (Federal)

Retatrutide is not FDA-approved and is not on any bulk substances list for compounding. It is an investigational drug in active Phase III trials. Compounding pharmacies cannot legally compound retatrutide under federal law. Providers offering it outside of a formal clinical trial operate without federal regulatory authorization.

Also Known As

LY3437943

Primary Research Areas

Weight loss
Obesity management
Metabolic syndrome
Type 2 diabetes

Pennsylvania Pharmacy Board & Compounding Rules

Regulator

Pennsylvania State Board of Pharmacy (PSBP)

Compounding Overview

Pennsylvania's State Board of Pharmacy regulates compounding pharmacies with detailed sterile and non-sterile compounding standards. Pennsylvania has historically been home to several large-scale compounding operations. The state enforces USP 797 standards for sterile products and requires annual inspections for high-risk compounding. Pennsylvania is part of the northeastern corridor with significant demand from New York, New Jersey, and Delaware markets.

Notable Rules

Pennsylvania requires pharmacies engaged in sterile compounding to have a separate license category.
Annual inspections are required for pharmacies performing high-risk sterile compounding.
Pennsylvania shares regulatory burden with the FDA for pharmacies also registered as 503B outsourcing facilities.
Non-resident pharmacies shipping compounds into Pennsylvania must be registered with the PSBP.
Pennsylvania and New York maintain some reciprocal licensing arrangements for pharmacy professionals.

Prescribing Requirements in Pennsylvania

Pennsylvania certified registered nurse practitioners (CRNPs) may prescribe compounded medications including peptides within a collaborative agreement. Physician assistants also require supervision agreements. Pennsylvania has moderately permissive telehealth rules, allowing prescribing after an appropriate telehealth evaluation. Pennsylvania prescribers must hold an active Pennsylvania license to prescribe to Pennsylvania residents.

About Retatrutide

Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. Phase II trials reported average weight loss of approximately 24% at the highest dose over 48 weeks. Phase III trials are ongoing as of 2026.

For more research information, mechanism of action, and provider availability, see the Retatrutide research profile on PeptideBase.

Frequently Asked Questions

Is retatrutide available to the public?: Retatrutide is not FDA-approved and is not legally available outside of clinical trials. Some providers may offer it under research or "off-label investigational" frameworks, but this carries significant legal and safety risk. Verify any provider's authorization carefully.
When might retatrutide receive FDA approval?: Phase III trials are ongoing as of 2026. FDA approval, if granted, would follow Phase III completion and NDA review — typically 1–3 years after Phase III initiation. Monitor ClinicalTrials.gov for updates.

Retatrutide Providers in Pennsylvania

1 provider in the PeptideBase directory offer Retatrutide in Pennsylvania. Always verify current offerings directly with the provider.

Clinic
Meeting Point Health
Philadelphia, United States
RecoveryCognitive+5
Meeting Point Health is a regenerative and functional medicine clinic offering peptide therapy, stem cell therapy, IV treatments, and orthopedic injections to address root causes of health conditions. Led by Dr. Stephen Matta (board-certified in primary care, non-surgical orthopedics, and stem cell therapy) and Mary Anne Matta (acupuncturist and functional medicine practitioner), the practice serves patients seeking personalized longevity and wellness optimization. The clinic is located in the Philadelphia area and does not accept insurance.
Verified4.8168GoogleView →

View all Retatrutide providers nationwide →

Retatrutide Legal Status in Other States

Pharmacy board rules and compounding regulations vary by state. Compare Retatrutide legal status across other major markets:

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: May 10, 2026.